ANAFILAXIA
Palabras clave:
Anafilaxia. Doença alérgica. Adrenalina. Emergência clínica.Resumen
A anafilaxia constitui uma reação sistêmica, severa, potencialmente fatal e com importante impacto na qualidade de vida dos pacientes. Recentes estudos mostram aumento da incidência e prevalência da doença. O manejo inicial é baseado nas manifestações clínicas. Os exames complementares são indicados para a investigação do agente desencadeante. A adrenalina, base de seu tratamento, apresenta boa resposta clínica quando devidamente administrada. Com abordagem emergencial, a anafilaxia é tema de necessário domínio entre os clínicos. Esse trabalho tem o objetivo de revisar o diagnóstico e abordagem terapêutica da anafilaxia incluindo os últimos consensos sobre o tema.Referencias
Simons FER, Ardusso LRF, Bilo MB et al. International consensus on (ICON) anaphylaxis. World Allergy Organization Journal 2014, 7:9.
Muraro A, Roberts G, Worm, M et al. Anaphylaxis: guidalines from the European Academy of Allergy and Clinical Immunology. European Journal of Alergy and Clinical Immunology, 2014; 69: 1026-1045.
Tallo FS, Graff S, Vendrame LS, Lopes RD, Lopes AC. Anafilaxia: reconhecimento e abordagem. Uma revisão para o clínico. Rev Bras Clin Med. São Paulo, 2012 jul-ago; 10 (4): 329-33.
Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125: S161-81.
Gupta RS. Anaphylaxis in the Young Population. The American Journal of Medicine, 2014; 127: 17-24.
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134: 1318-28.
Wölbing F, Biedermann T. Anaphylaxis: opportunities of stratified medicine for diagnosis and risk assesment. Allergy 2013; 69: 1499-1508.
Bernd LAG, Sá AB, Watanabe AS et al. Guia Prático para o Manejo de Anafilaxia – 2012. Revista Bras. Alergia e Imunologia, 2012; 35 (2): 53-70.
Martins HS et al. Emergêcias clínicas: abordagem prática. 8ed. rev e atual. Barueri, SP, Manole, 2013.
Lieberman PL. Recognition and First-Line Treatment of Anaphylaxis. The American Journal of Medicine, 2014; 127: 6-11.
Simons FE, Camargo CA. Anaphylaxis: Rapid recognition and treatment. Uptodate, dezembro de 2014.
Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117: 367-377.
Park HJ, Kim SH. Factors associated with shock in anaphylaxis. American Journal of Emergency Medicine, 2012; 30 1674-1678.
Clark S, Wei W, Rudders AS, Camargo CA. Risk factores for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. J Allergy Clin Immunol 2014; 134: 1125-30.
Pérez AG, Rodríguez LAG. Anaphylaxis epidemiology in patients with and patients without asthma: A United Kngdom database review. J Allergy Clin Immunol 2010; 125 (5): 1098-1104.
Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clinical Et Experimental Allergy, 2014; 44: 914-920.
Lieberman P, Simons FER. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. Clin Exp Allergy, 2015.
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391-397.
Sampson HA, Muñoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584-591.
Campbell RL, Hagan JB, Manivannan V, et al. Evaluation of national institute of allergy and infectious diseases/food allergy and anaphylaxis network criteria for the diagnosis of anaphylaxis in emergency department patients. J Allergy Clin Immunol 2012; 129:748-752.
Sclar DA, Lieberman PL. Anaphylaxis: Underdiagnosed, underreported, and undertreated. The American Journal of Medicine, 2014; 127: 1-5.
Sampson MA, Munoz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol. 2006; 117: 1440-1445.
Russell WS, Farrar JR, Nowak R et al. Evaluating the management of anaphylaxis in US emergency departments: guidelines VS practice. World J Emerg Med, 2013; 4 (2): 98-106.
Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am, 2006; 26:451-463.
Simons FER. Anaphylaxis pathogenesis and treatment. Alergy, 2011; 66 (Suppl. 95): 31-34.
Simons FER. Anaphylaxis: Recent advances in assessment and treatment. J Allergy Clin Immunol, 2009; 124: 625-636.
Pastorino AC, Rizzo MC, Rubini N et al. Projeto Diretrizes. Anafilaxia: tratamento. Associação Brasileira de Alergia e Imunopatologia e Sociedade Brasileira de Anestesiologia, 2011.
Nowak RM, Macias CG. Anaphylaxis on the other front line: Perspectives from the Emergency Department. The American Journal of Medicine, 2014; 127: 34-44 .
Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev 2012; 4:CD007596. 8ed.
Sicherer SH, Simons FER. Self-injectable Epinephrine for First-Aid Management of Anaphylaxis. Pediatrics, 2007; 119 (3): 638-646.
Zilberstein J, McCurdy MT, Winters ME. Anaphylaxis. The Journal of Emergency Medicine, 2014; 47 (2): 182-187.
Dhami S, Panesar SS, Roberts G et al. Management of anaphylaxis: a systematic review. Allergy, 2014 (69): 168-175.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2017 Arquivos Catarinenses de Medicina
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
